NCT06191887 - B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2024

Primary Completion Date

December 31, 2040

Study Completion Date

December 31, 2040

Conditions

B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaRefractory Small Lymphocytic LymphomaRefractory Transformed Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

Autologous BAFFR-targeting CAR T Cells

Given IV

DRUG

Bendamustine

Given IV

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow biopsy/aspirate

PROCEDURE

Computed Tomography

Undergo CT scan

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography

Undergo echocardiography

DRUG

Fludarabine

Given IV

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET scan

Trial Locations (1)

32224-9980

RECRUITING

Mayo Clinic in Florida, Jacksonville